Abstract
Objective: To investigate the effects of the DNA methyltransferase inhibitor 5-Aza-2'- Deoxycytidine (5-Aza-Dc) on DLC-1 gene expression, methylation level, and the expression of downstream signaling molecules Cdc42 in the human multiple myeloma cell line RPMI8226 cells.
Methods: The RPMI8226 cells were treated with 5-Aza-Dc, the methylation status of CpG island of DLC-1 gene was detected by bisulfate sequencing PCR(BSP) in RPMI8226 cells. The expression of DLC-1 and Cdc42 mRNA was determined by reverse transcriptase polymerase chain reaction (RT-PCR). Enzyme-linked immunoabsorbent assay (ELISA) was used to detect the expression of Cdc42 protein.
Results: The methylation of DLC-1 gene was detected in the RPMI8226 cells without 5-Aza-Dc pretreament. DLC-1 gene methylation status was decreased after the 5-Aza-Dc treatment for 72h, and DLC-1 gene didn't display DNA methylation on the highest concentration of 5-Aza-Dc. DLC-1 mRNA was weakly expressed in the control group, and the expression was gradually increased in 5-Aza-Dc treatment group. The Cdc42 mRNA and protein expression of experimental group were significantly decreased and were dose-dependent compared with the control group (P <0.05).
Conclusion: The results of this research indicated that 5-Aza-Dc can effectively inhibit the methylation status of DLC-1 gene, reversal DLC-1 gene expression, and significantly decrease the expression of downstream signaling molecules Cdc42 mRNA and protein in RPMI-8226 cell.
Keywords: 5-aza-2`-deoxycytidine, Cdc42, DLC-1, methylation, multiple myeloma.
Current Signal Transduction Therapy
Title:The Effects of 5-Aza-2`-Deoxycytidine on DLC-1 Gene Expression, Methylation Level and Expression of Downstream Signaling Molecules Cdc42 in Multiple Myeloma
Volume: 10 Issue: 1
Author(s): Xianqi Feng, Ling Zhang, Shumin Nie, Zhan Su, Xue Shi, Yan Gao, Xiangyun Chen, Wenyuan Niu, Zhongguang Cui, Hongguo Zhao, Fanjun Meng and Chunting Zhao
Affiliation:
Keywords: 5-aza-2`-deoxycytidine, Cdc42, DLC-1, methylation, multiple myeloma.
Abstract: Objective: To investigate the effects of the DNA methyltransferase inhibitor 5-Aza-2'- Deoxycytidine (5-Aza-Dc) on DLC-1 gene expression, methylation level, and the expression of downstream signaling molecules Cdc42 in the human multiple myeloma cell line RPMI8226 cells.
Methods: The RPMI8226 cells were treated with 5-Aza-Dc, the methylation status of CpG island of DLC-1 gene was detected by bisulfate sequencing PCR(BSP) in RPMI8226 cells. The expression of DLC-1 and Cdc42 mRNA was determined by reverse transcriptase polymerase chain reaction (RT-PCR). Enzyme-linked immunoabsorbent assay (ELISA) was used to detect the expression of Cdc42 protein.
Results: The methylation of DLC-1 gene was detected in the RPMI8226 cells without 5-Aza-Dc pretreament. DLC-1 gene methylation status was decreased after the 5-Aza-Dc treatment for 72h, and DLC-1 gene didn't display DNA methylation on the highest concentration of 5-Aza-Dc. DLC-1 mRNA was weakly expressed in the control group, and the expression was gradually increased in 5-Aza-Dc treatment group. The Cdc42 mRNA and protein expression of experimental group were significantly decreased and were dose-dependent compared with the control group (P <0.05).
Conclusion: The results of this research indicated that 5-Aza-Dc can effectively inhibit the methylation status of DLC-1 gene, reversal DLC-1 gene expression, and significantly decrease the expression of downstream signaling molecules Cdc42 mRNA and protein in RPMI-8226 cell.
Export Options
About this article
Cite this article as:
Feng Xianqi, Zhang Ling, Nie Shumin, Su Zhan, Shi Xue, Gao Yan, Chen Xiangyun, Niu Wenyuan, Cui Zhongguang, Zhao Hongguo, Meng Fanjun and Zhao Chunting, The Effects of 5-Aza-2`-Deoxycytidine on DLC-1 Gene Expression, Methylation Level and Expression of Downstream Signaling Molecules Cdc42 in Multiple Myeloma, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1574362410666150311000910
DOI https://dx.doi.org/10.2174/1574362410666150311000910 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Current Cancer Therapy Reviews Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation
Current Pharmaceutical Design Expression, Purification and Characterization of Recombinant Toxins Consisting of Truncated Gastrin 17 and Pseudomonas Exotoxin
Protein & Peptide Letters Targeting Notch as a Therapeutic Approach for Human Malignancies
Current Pharmaceutical Design Recent Advances on the Enantioselective Synthesis of C-Nucleosides Inhibitors of Inosine Monophosphate Dehydrogenase (IMPDH)
Current Topics in Medicinal Chemistry Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry The Clinical Characteristics and Survival Profiles of Wilms Tumor in the United Arab Emirates: A Single-center Retrospective Analysis
New Emirates Medical Journal Utilization of Analytical Omics Tools in the Molecular Diagnostics of Multiple Myeloma
Current Molecular Medicine Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy